Clinical Trial Detail

NCT ID NCT03133390
Title Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors New York University School of Medicine
Indications

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

urethra transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Atezolizumab + Bevacizumab

Atezolizumab

Age Groups: adult senior

No variant requirements are available.